141 related articles for article (PubMed ID: 22714719)
21. Translational research in oncology: key bottlenecks and new paradigms.
Simon R
Expert Rev Mol Med; 2010 Oct; 12():e32. PubMed ID: 20929594
[TBL] [Abstract][Full Text] [Related]
22. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
23. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the efficiency of targeted designs for randomized clinical trials.
Simon R; Maitournam A
Clin Cancer Res; 2004 Oct; 10(20):6759-63. PubMed ID: 15501951
[TBL] [Abstract][Full Text] [Related]
25. Genomic Alteration-Driven Clinical Trial Designs in Oncology.
Simon R
Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515
[TBL] [Abstract][Full Text] [Related]
26. Phase III trials of targeted anticancer therapies: redesigning the concept.
Ocana A; Amir E; Vera-Badillo F; Seruga B; Tannock IF
Clin Cancer Res; 2013 Sep; 19(18):4931-40. PubMed ID: 23881926
[TBL] [Abstract][Full Text] [Related]
27. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
28. New designs for basket clinical trials in oncology.
Simon R
J Biopharm Stat; 2018; 28(2):245-255. PubMed ID: 28877003
[TBL] [Abstract][Full Text] [Related]
29. A two-stage Bayesian design for co-development of new drugs and companion diagnostics.
Karuri SW; Simon R
Stat Med; 2012 May; 31(10):901-14. PubMed ID: 22238151
[TBL] [Abstract][Full Text] [Related]
30. Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies.
Rowinsky EK
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4220s-4226s. PubMed ID: 15217962
[TBL] [Abstract][Full Text] [Related]
31. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
32. [The designs of exploratory biomarker study].
Gosho M; Nagashima K; Sato Y
Nihon Rinsho; 2012 May; 70(5):874-9. PubMed ID: 22620016
[TBL] [Abstract][Full Text] [Related]
33. Multi-arm clinical trials of new agents: some design considerations.
Freidlin B; Korn EL; Gray R; Martin A
Clin Cancer Res; 2008 Jul; 14(14):4368-71. PubMed ID: 18628449
[TBL] [Abstract][Full Text] [Related]
34. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
35. Marker Sequential Test (MaST) design.
Freidlin B; Korn EL; Gray R
Clin Trials; 2014 Feb; 11(1):19-27. PubMed ID: 24085774
[TBL] [Abstract][Full Text] [Related]
36. Drug research: from the idea to the product.
Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
[TBL] [Abstract][Full Text] [Related]
37. Adaptive methods: telling "the rest of the story".
Emerson SS; Fleming TR
J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
[TBL] [Abstract][Full Text] [Related]
38. Improving the outcomes: developing cancer therapeutics.
Utku N
Future Oncol; 2012 Jan; 8(1):87-103. PubMed ID: 22149037
[TBL] [Abstract][Full Text] [Related]
39. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
40. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
